Trials / Completed
CompletedNCT01467271
Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 540 (actual)
- Sponsor
- Guerbet · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to prospectively estimate the incidence of Nephrogenic Systemic Fibrosis (NSF) in patients with moderate to severe renal impairment after administration of Dotarem®
Detailed description
All patients will be followed up during 2 years after Dotarem® administration to collect data on any suspected NSF or NSF-related symptoms
Conditions
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2011-11-08
- Last updated
- 2019-02-04
- Results posted
- 2019-02-04
Locations
27 sites across 11 countries: United States, Argentina, Belgium, Colombia, France, Germany, Italy, South Korea, Spain, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01467271. Inclusion in this directory is not an endorsement.